Search hospitals > New Jersey > Somerville
Robert Wood Johnson University Hospital Somerset
Claim this profileSomerville, New Jersey 08876
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
120 reported clinical trials
15 medical researchers
Summary
Robert Wood Johnson University Hospital Somerset is a medical facility located in Somerville, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Robert Wood Johnson University Hospital Somerset is involved with conducting 120 clinical trials across 156 conditions. There are 15 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Mridula George, MD.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Eugenia Girda, MDRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Cancer
Studies Serous Cystadenocarcinoma
13 reported clinical trials
27 drugs studied
Mridula George, MDRutgers Cancer Institute of New Jersey1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
19 drugs studied
Clinical Trials running at Robert Wood Johnson University Hospital Somerset
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Colon Cancer
Colorectal Cancer
Prostate Adenocarcinoma
Small Cell Lung Cancer
Recurrence
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Robert Wood Johnson University Hospital Somerset?
Robert Wood Johnson University Hospital Somerset is a medical facility located in Somerville, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Robert Wood Johnson University Hospital Somerset is involved with conducting 120 clinical trials across 156 conditions. There are 15 research doctors associated with this hospital, such as Howard S. Hochster, Missak Haigentz, MD, Eugenia Girda, MD, and Mridula George, MD.